AZN vs MRK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
AZN · AstraZeneca$186.43 ▼ 0.22%
MRK · Merck & Co$146.73 ▼ 0.14%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- AZN +8.4%
- MRK +73.1%
Head to head
| Metric | AZN | MRK |
|---|---|---|
| Price | $186.43 | $146.73 |
| Change today | ▼ 0.22% | ▼ 0.14% |
| Market cap | $289.14B | $361.73B |
| Return, 3 months | +15.1% | +12.1% |
| Return, year to date | +3.1% | +41.4% |
| Return, 1 year | +12.1% | +74.0% |
| P/E (TTM) | 26.4 | 148.2 |
| P/B | 5.6 | 8.1 |
| P/E percentile vs own 5y | 21st | 95th |
| Dividend yield | 1.73% | 2.32% |
| Revenue growth (YoY, latest qtr) | +6.4% | +4.7% |
| Net profit growth (YoY) | +2.5% | -12.4% |
| Gross margin | 81.9% | 71.8% |
| Operating margin | 22.1% | 9.2% |
| Net margin | 17.0% | 3.6% |
| Return on equity | 22.0% | – |
| Analyst target vs. price | +17.8% | +14.1% |
| Analyst buy share | 86% | 79% |
| RSI (14) | 69 | 51 |
| 30-day volatility | 32.1% | 33.2% |
| Max drawdown, 1 year | -25.3% | -11.4% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- MRK is the largest of the group by market value.
- MRK has returned the most over the past year.
- AZN carries the lowest trailing P/E.
- MRK pays the highest dividend yield.
- AZN is growing revenue fastest.
- AZN keeps the most profit per dollar of sales.
- AZN has been the calmest stock over the last 30 days.